Tabrecta: Uses, Dosage & Side Effects

What Is Tabrecta and How Does It Work?

Tabrecta (capmatinib) belongs to a class of medications known as protein kinase inhibitors, specifically targeting the MET (mesenchymal-epithelial transition) receptor tyrosine kinase. It is indicated for the treatment of adult patients with advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors harbor MET exon 14 skipping mutations, as detected by a validated test. NSCLC accounts for approximately 80–85% of all lung cancers, and MET exon 14 skipping mutations are found in approximately 3–4% of NSCLC cases, representing a distinct molecular subtype that drives tumor growth through constitutive activation of the MET pathway.

The MET receptor is a transmembrane receptor tyrosine kinase that, under normal physiological conditions, plays important roles in embryonic development, tissue repair, and organ regeneration. When the MET gene harbors exon 14 skipping mutations, the resulting protein lacks the juxtamembrane domain responsible for ubiquitin-mediated degradation. This leads to prolonged MET receptor activation and sustained downstream signaling through pathways such as RAS/RAF/MAPK and PI3K/AKT, which promote cell proliferation, survival, migration, and invasion. Capmatinib potently and selectively inhibits MET phosphorylation and blocks these downstream oncogenic signaling cascades.

Capmatinib was developed as a first-in-class selective MET inhibitor and received accelerated approval from the U.S. Food and Drug Administration (FDA) in May 2020 based on results from the GEOMETRY mono-1 clinical trial. This pivotal phase II, multicenter, non-randomized, open-label, multi-cohort study evaluated capmatinib in patients with advanced NSCLC harboring MET exon 14 skipping mutations or MET amplification. Among treatment-naive patients with MET exon 14 skipping mutations, the overall response rate (ORR) was 68%, with a complete response rate of 4%. In previously treated patients, the ORR was 41%. The European Medicines Agency (EMA) subsequently granted marketing authorization for Tabrecta based on this and additional clinical evidence.

Before initiating treatment with Tabrecta, patients must undergo molecular testing to confirm the presence of MET exon 14 skipping mutations. This testing can be performed on tumor tissue obtained through biopsy or on circulating tumor DNA (ctDNA) from a blood sample (liquid biopsy) using validated next-generation sequencing (NGS) or RNA-based assays. The identification of this specific molecular alteration is essential, as Tabrecta is effective only in tumors driven by this particular mutation. If a liquid biopsy result is negative, tissue biopsy should be considered to confirm the finding, as liquid biopsy may have limited sensitivity depending on the tumor shedding rate and circulating tumor DNA levels.

Tabrecta represents a significant advance in precision oncology for patients with MET-driven NSCLC, who historically had limited targeted treatment options. Unlike broad-spectrum tyrosine kinase inhibitors, capmatinib's high selectivity for MET helps to reduce off-target effects while maximizing on-target therapeutic activity. Treatment with Tabrecta is continued for as long as the patient derives clinical benefit or until unacceptable toxicity occurs, and the medication is taken continuously as an oral therapy, making it convenient for long-term use in the outpatient setting.

What You Should Know Before Taking Tabrecta

Contraindications

Tabrecta is contraindicated in patients with known hypersensitivity to capmatinib or to any of the excipients contained in the tablet formulation. If you have previously experienced an allergic reaction to capmatinib or any component of Tabrecta tablets, you should not take this medication. Allergic reactions can range from mild skin rashes and urticaria to severe systemic reactions including fever, breathing difficulties, and hypotension. Any signs of a hypersensitivity reaction should be reported to your healthcare provider immediately, and treatment should be discontinued if a serious allergic reaction occurs.

Important Warnings and Precautions

Pancreatic toxicity: Elevated levels of amylase and lipase (pancreatic enzymes) have been commonly observed during treatment with Tabrecta. Your doctor will monitor these levels through regular blood tests. In rare cases, acute pancreatitis may develop. Seek immediate medical attention if you experience severe abdominal pain that radiates to your back, nausea, or vomiting, as these may be signs of pancreatitis.

Renal impairment: Cases of renal failure and acute kidney injury have been reported. Your kidney function will be monitored during treatment with regular blood tests measuring creatinine levels. Adequate hydration is recommended, and your doctor will assess renal function periodically throughout the course of therapy.

Use in Specific Populations

Children and adolescents: Tabrecta is not indicated for use in patients under 18 years of age. The safety and efficacy of capmatinib in pediatric populations have not been established. MET exon 14 skipping mutations in NSCLC predominantly occur in older adults, and this medication should only be used in adult patients.

Pregnancy and fertility: Tabrecta may cause harm to an unborn baby. Based on its mechanism of action and findings from animal reproduction studies, capmatinib can cause embryo-fetal toxicity. Women of childbearing potential must use effective contraception during treatment with Tabrecta and for at least 7 days after the last dose. A pregnancy test should be performed before starting treatment. If you become pregnant while taking Tabrecta, inform your doctor immediately. Male patients with female partners of childbearing potential should use condoms during treatment and for at least 7 days after the last dose.

Breastfeeding: It is not known whether capmatinib or its metabolites are excreted in human breast milk. A risk to breastfed infants cannot be excluded. Breastfeeding should be discontinued during treatment with Tabrecta and for at least 7 days after the last dose. Discuss the benefits and risks with your healthcare provider.

Driving and operating machinery: Tabrecta is not expected to significantly affect your ability to drive or operate machinery. However, if you experience fatigue, dizziness, or other side effects that may impair your ability to perform these activities safely, you should avoid driving or operating machinery until the symptoms resolve.

Sodium content: Tabrecta contains less than 1 mmol sodium (23 mg) per tablet, meaning it is essentially sodium-free. This is relevant for patients on a controlled sodium diet.

Drug Interactions

Capmatinib is primarily metabolized by the cytochrome P450 enzyme CYP3A4 and is also a substrate of P-glycoprotein (P-gp). Additionally, capmatinib inhibits CYP1A2, P-gp, BCRP (breast cancer resistance protein), MATE1 (multidrug and toxin extrusion protein 1), and MATE2-K. These pharmacokinetic properties lead to numerous clinically significant drug interactions that must be carefully managed. It is critical that you inform your oncologist about every medication you are taking, including prescription drugs, over-the-counter medications, herbal supplements, and vitamins.

Concomitant use of strong CYP3A4 inducers significantly reduces capmatinib plasma concentrations, which may decrease the therapeutic efficacy of Tabrecta. Concomitant use of strong CYP3A4 inhibitors can increase capmatinib plasma concentrations, potentially increasing the risk and severity of adverse reactions. Moderate CYP3A4 inhibitors may also increase capmatinib levels to a clinically relevant degree and should be used with caution.

Capmatinib's inhibition of CYP1A2 can substantially increase the plasma concentrations of co-administered CYP1A2 substrates with narrow therapeutic indices, such as theophylline and tizanidine. This can lead to serious toxicity. Similarly, capmatinib's inhibition of drug transporters (P-gp, BCRP, MATE1, MATE2-K) can increase systemic exposure to substrates of these transporters, necessitating dose adjustments or avoidance of certain combinations.

How to Take Tabrecta: Dosage and Administration

The recommended dose of Tabrecta for adult patients is 400 mg (two 200 mg film-coated tablets) taken orally twice daily, resulting in a total daily dose of 800 mg. Tablets should be swallowed whole with water and must not be split, crushed, or chewed, as this could alter the drug's release profile and pharmacokinetic properties. Tabrecta can be taken with or without food, as food does not significantly affect the absorption of capmatinib. For optimal therapeutic benefit, it is recommended to take doses at approximately the same times each day, roughly 12 hours apart, to maintain consistent drug concentrations in the blood.

Treatment with Tabrecta is intended as long-term therapy and is continued for as long as the patient experiences clinical benefit or until unacceptable toxicity occurs. The duration of treatment can extend over many months or even years in patients who respond well to therapy. Your oncologist will regularly assess your response to treatment through imaging studies and clinical evaluation to determine whether continuation of Tabrecta is appropriate. Regular blood tests will also be performed to monitor for potential toxicities, including liver function tests and pancreatic enzyme levels.

Dose modifications may be necessary in response to adverse reactions. Your oncologist may reduce the dose, temporarily withhold treatment, or permanently discontinue Tabrecta depending on the type and severity of the side effect. The dose reduction schedule typically follows a stepwise approach: from 400 mg twice daily to 300 mg twice daily, then to 200 mg twice daily if further reduction is needed. If the adverse reaction requires dose reduction below 200 mg twice daily, permanent discontinuation of Tabrecta is recommended.

Pediatric use: Tabrecta is not approved for use in children and adolescents under 18 years of age. The safety, efficacy, and pharmacokinetic profile of capmatinib have not been established in pediatric patients. MET exon 14 skipping mutations in NSCLC are predominantly an adult-onset molecular alteration, and clinical trials have not included pediatric populations.

What Are the Side Effects of Tabrecta?

Like all medications, Tabrecta can cause side effects, although not everybody experiences them. The side effect profile of capmatinib has been characterized through clinical trials, most notably the GEOMETRY mono-1 study, which enrolled patients with advanced NSCLC harboring MET alterations. Understanding the frequency, nature, and management of these side effects is essential for patients and caregivers. Most side effects are manageable through dose adjustments, temporary treatment interruptions, or supportive care measures. Your oncology team will monitor you closely for potential adverse reactions through regular clinic visits and blood tests.

Side effects are classified below by frequency, based on the following convention: very common (affects more than 1 in 10 people), common (affects 1 to 10 in every 100 people), uncommon (affects 1 to 10 in every 1,000 people), rare (affects 1 to 10 in every 10,000 people). Laboratory abnormalities detected through blood tests are included alongside clinical symptoms, as they may indicate organ toxicity that requires intervention even in the absence of symptoms.

Many side effects can be managed effectively with supportive care. Nausea and vomiting may be controlled with antiemetic medications prescribed by your doctor. Peripheral edema can often be managed with elevation of the affected limbs and, in some cases, diuretic therapy. Fatigue is one of the most common complaints and may be improved through activity pacing, adequate rest, and maintaining regular light exercise as tolerated. Diarrhea should be treated promptly with antidiarrheal agents and adequate fluid intake to prevent dehydration. If any side effect becomes severe, persistent, or bothersome, always discuss it with your healthcare team, as dose adjustments may help improve tolerability while maintaining treatment efficacy.

Laboratory abnormalities, particularly elevated liver enzymes (ALT, AST) and pancreatic enzymes (amylase, lipase), are among the most frequently observed adverse findings during treatment with Tabrecta. These elevations are often asymptomatic and detected only through routine blood monitoring, underscoring the importance of adhering to your scheduled laboratory appointments. Your oncologist will use established grading criteria (such as CTCAE) to classify the severity of these abnormalities and determine whether dose modification or treatment interruption is necessary. In most cases, enzyme elevations are reversible with appropriate management.

How to Store Tabrecta

Proper storage of Tabrecta is essential to maintain the medication's stability, safety, and effectiveness throughout the treatment period. Like all medications, Tabrecta should be kept out of the sight and reach of children and pets. Store the tablets in the original blister packaging to protect them from moisture, as capmatinib is sensitive to humidity. Do not transfer tablets to another container such as a pill organizer unless instructed to do so by your pharmacist.

Tabrecta does not require any special temperature storage conditions. However, it should be stored at room temperature and protected from excessive heat and humidity. Do not store the medication in bathrooms, near kitchen sinks, or in other damp environments. Always check the expiry date printed on the packaging before taking a tablet. Do not use Tabrecta after the expiry date has passed, as the medication may have degraded and may no longer be effective or safe.

If the blister packaging appears damaged, punctured, or compromised in any way, do not use the affected tablets and consult your pharmacist for a replacement. Dispose of any unused or expired medication properly – do not flush tablets down the toilet or throw them in household waste. Ask your pharmacist about local medication take-back programs or proper disposal methods to protect the environment and prevent accidental exposure to others.

What Does Tabrecta Contain?

The active substance in Tabrecta is capmatinib, present as capmatinib dihydrochloride monohydrate. Tabrecta is available in two strengths: 150 mg and 200 mg film-coated tablets. Each tablet is formulated with specific excipients (inactive ingredients) that serve different functions in the tablet manufacturing process, including ensuring proper tablet cohesion, disintegration, and stability.

Tablet Identification

Excipients (Inactive Ingredients)

Tablet core: microcrystalline cellulose, mannitol, crospovidone, povidone, magnesium stearate, colloidal anhydrous silica, sodium lauryl sulfate.

150 mg tablet film coating: hypromellose, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172), red iron oxide (E172), black iron oxide (E172).

200 mg tablet film coating: hypromellose, titanium dioxide (E171), macrogol, talc, yellow iron oxide (E172).

Pack sizes: Tabrecta is supplied in blister packs containing 60 or 120 film-coated tablets. Not all pack sizes may be marketed in all countries. The blister packaging is designed to protect the tablets from moisture and maintain stability throughout the shelf life of the product.

Marketing Authorization Holder: Novartis Europharm Limited, Dublin, Ireland. Tabrecta is manufactured by Novartis and distributed internationally through various subsidiaries and distribution partners. For detailed information about the marketing authorization in your country, refer to your national medicines regulatory authority or consult your pharmacist.